In the United States, a<unk>  (sometimes "black box<unk> ", colloquially) is a type of<unk>  that appears on the package insert for certain prescription drugs, so called because the U.S. Food and Drug Administration specifies that it is formatted with a 'box' or border around the text. The FDA can require a pharmaceutical company to place a<unk>  on the labeling of a prescription drug, or in literature describing it. It is the strongest<unk>  that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects. Economists and physicians have thoroughly studied the effects of FDA<unk> s on prescription patterns. It is not necessarily true that a physician and patient will have a conversation about a drug's<unk>  after it is issued. For instance, an FDA-mandated<unk>  decreased rosiglitazone use by 70%, but that still meant 3.8 million people were given the drug. Later research indicated that after receiving an FDA advisory, there was a decrease in rosiglitazone use, due to a combined effect of media exposure, advisory, and scientific publications, whereas pioglitazone (with a similar advisory but less media exposure) did not similarly decrease in use. In 2005, the FDA issued a<unk>  regarding the risk of atypical antipsychotics being prescribed among elderly patients with dementia. This advisory was associated with a decrease in use of antipsychotics, especially in elderly patients with dementia.
Boxed warning
Certified first responder
Accident
Actifed
Drug coupon
Slow code
SafeEntry
Emergency service response codes